Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, a clinical stage biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare ...

Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...